Clinical trial · no report yet · Phase 3
OlympiAD
Assessment of the Efficacy and Safety of Olaparib Monotherapy Versus Physicians Choice Chemotherapy in the Treatment of Metastatic Breast Cancer Patients With Germline BRCA1/2 Mutations.
- NCT02000622 ↗
- Completed
- AstraZeneca
- 65 commentary sources found
- Deep
We haven't built a report for this trial yet. This page shows the registry record and the public commentary we found that names the trial. A report reads that commentary and sets out what clinicians said about the trial, each point linked to its source. How reports are made.
Commentary we found
Podcasts, YouTube videos and X posts in our index that name this trial. A report screens them, searches for more and cites what clinicians said when it is built.
| Channel | Found | |
|---|---|---|
| YouTube | 35 | |
| Podcasts | 24 | |
| X threads | 6 |
The trial
ClinicalTrials.gov- Official title
- A Phase III, Open Label, Randomised, Controlled, Multi-centre Study to Assess the Efficacy and Safety of Olaparib Monotherapy Versus Physicians Choice Chemotherapy in the Treatment of Metastatic Breast Cancer Patients With Germline BRCA1/2 Mutations.
- Phase
- Phase 3
- Status
- Completed
- Conditions
- Breast Cancer Metastatic; BRCA 1 Gene Mutation; BRCA 2 Gene Mutation
- Interventions
- Olaparib; Physician's choice chemotherapy
- Arms
- Olaparib · Experimental
- Physician's choice chemotherapy · Active comparator
- Enrollment
- 302
- Primary outcomes
- Progression-free Survival (PFS) Using Blinded Independent Central Review (BICR) According to Modified Response Evaluation Criteria In Solid Tumours (RECIST v1.1)
- Sponsor
- AstraZeneca with Myriad Genetic Laboratories, Inc., Merck Sharp & Dohme LLC
- Start
- Mar 27, 2014
- Primary completion
- Dec 9, 2016
- Results posted
- Yes
- Registry record
- NCT02000622 · updated Feb 13, 2026
Publications
linked from the registry- Robson M, Im SA, Senkus E, Xu B, Domchek SM, Masuda N, Delaloge S, Li W, Tung N, Armstrong A, Wu W, Goessl C, Runswick S, Conte P. Olaparib for Metastatic Breast Cancer in Patients with a Germline BRCA Mutation. N Engl J Med. 2017 Aug 10;377(6):523-533. doi: 10.1056/NEJMoa1706450. Epub 2017 Jun 4. PubMed 28578601